J

Jianjun Gao

Qingdao University

ORCID: 0000-0001-6138-4472

Publishes on Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments. 521 papers and 21.9k citations.

521Publications
21.9kTotal Citations

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
Jianjun Gao, Zhenxue Tian, Xu Yang|BioScience Trends|2020
Cited by 2.7kOpen Access

The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future.

Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Liying Dong, Shasha Hu, Jianjun Gao|Drug Discoveries & Therapeutics|2020
Cited by 1.5kOpen Access

The SARS-CoV-2 virus emerged in December 2019 and then spread rapidly worldwide, particularly to China, Japan, and South Korea. Scientists are endeavoring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far. This article summarizes agents with potential efficacy against SARS-CoV-2.